CTNM vs GYRE
CTNM: A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for depression and multiple sclerosis. GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market.
Side-by-side fundamentals
| Metric | CTNM | GYRE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.73 | $5.94 | |
| Market cap as of 2026-07-23 | $518M | $667M | |
| P/E as of 2026-07-23 | n/a | 132.62 | |
| PEG as of 2026-07-23 | -6.25 | n/a | |
| Net margin as of 2026-07-23 | +45.4% | -5.4% | CTNM higher |
| Gross margin as of 2026-07-23 | n/a | +95.1% | |
| Operating margin as of 2026-07-23 | +32.1% | -0.1% | CTNM higher |
| ROE as of 2026-07-23 | -27.1% | -6.3% | GYRE higher |
| ROA as of 2026-07-23 | -25.6% | -4.0% | GYRE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +16.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.62 | 2.36 | |
| 1-year return as of 2026-07-22 close | +146.0% | -17.8% | CTNM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.